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Abstract
Background: Leucine-rich-alpha-2-glycoprotein 1 (LRG1) has been reported to be involved in several tumors, whether
it participates in colorectal cancer (CRC) progression remains unclear. Here, we investigated the biological function and
underlying molecular mechanisms of LRG1 in CRC.
Methods: The mRNA and protein levels of LRG1 were assessed in CRC tissues through RT-PCR and immunohistochemistry,
respectively. HCT116 and SW480 cells were treated with LRG1 siRNA, control siRNA, or recombinant LRG1. Transwell
invasion assays and wound healing assays were performed to evaluate the invasion and migration of CRC cells.
Epithelial-to-mesenchymal transition (EMT) markers of E-cadherin, VDR, N-cadherin, α-SMA, Vimentin and Twist1 were
detected by RT-PCR and western blot. Enzyme-linked immunosorbent assay was used to measure the secretion level of
VEGF-A. Conditioned medium from CRC cells was collected for endothelial cell migration, tube formation and aortic
ring sprouting assays.
Results: LRG1 was overexpressed in CRC tissues and associated with cancer aggressiveness. LRG1 was further found to
induce the EMT process, as well as CRC cell migration and invasion capacity. In addition, LRG1 promoted VEGF-A
expression in CRC cells and contributed to tumor angiogenesis. Furthermore, HIF-1α could be induced by LRG1 in
a concentration- and time-dependent manner, which was responsible for LRG1-induced VEGF-A expression and EMT.
Conclusions: The present study suggests that LRG1 plays a crucial role in the progression of CRC by regulating HIF-1α
expression, thereby may be a promising therapeutic target of CRC.
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Background
Despite advances in early diagnosis and comprehensive
therapy, colorectal cancer (CRC) remains one of the lead-
ing causes of cancer death worldwide. The prognoses of
CRC patients were often poor due to recurrence and me-
tastasis, especially for those diagnosed at advanced stages.
The 5-year survival rate is only 12 % for CRC patients
with distant metastasis [1]. Hence, elucidating the molecu-
lar events involved in CRC and identifying novel bio-
marker and therapeutic targets is indispensible and urgent
for the clinical outcome of CRC.
Leucine-rich-alpha-2-glycoprotein1 (LRG1) is the found-
ing member of leucine-rich repeat (LRR) family, which was
first isolated from human serum in 1977 [2]. It is a secreted
glycoprotein and contains eight repeating consensus se-
quences, each of which consists of 24 amino acid residues
[3]. LRG1 has been reported to be involved in immune
response, cell proliferation, cell migration, cell apoptosis
and neovascularization [4–7]. LRG1 is overexpressed in
several types of carcinomas, including pancreatic, bladder,
ovarian, and biliary tract cancer [8–11]. LRG1 was shown
to bind to the transforming growth factor-beta (TGF-β)
accessory receptor and modulate Smad1/5/8 signalling
pathway, resulting in promotion of angiogenesis in endo-
thelial cells [7]. It was reported that LRG1 was a target of
miR-335 and contribute to the migratory and invasive
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ability of neuroblastoma cell [5]. However, little is known
about the biological function of LRG1 in colorectal cancer.
To reveal the signaling proteins downstream of LRG1,
we performed a gene microarray and found that several
key proteins involved in epithelial-to-mesenchymal tran-
sition (EMT) were affected by depletion of LRG1 in
CRC cells. EMT is a pathological process that epithelial
cells lose their characteristic of cell polarity and adhe-
sion, while acquire a mesenchymal phenotype [12]. EMT
process results in enhanced ability of mobility and inva-
siveness for carcinoma cells, which is considered as a
crucial early step in cancer progression and metastasis
[13–15]. Besides, hypoxia-inducible factor-1α (HIF-1α)
and vascular endothecial growth factor A (VEGF-A) was
significantly downregulated in LRG1-knockdown CRC
cells. HIF-1α is the oxygen-regulated subunit of HIF-1,
which is the most important transcriptional regulator in
response to hypoxia. HIF-1α participates in the key steps
in carcinogenesis such as cell survival, angiogenesis and
metastasis, through transcriptional activation of targeted
genes [16, 17]. Notably, HIF1α has been identified as an
important mediator of EMT in tumor cells via activation
of Twist, Snail, and SIP1 [18, 19]. The mechanisms
underlying HIF-1α-induced EMT in CRC have not been
completely determined. Therefore, LRG1 might be asso-
ciated with the EMT and angiogenesis in CRC.
In the present study, we investigated the expression
level of LRG1 in CRC tissues and explored the role of
LRG1 in CRC cell invasion, EMT, and endothelial cell
activities. We also aimed to validate the promotion effect
of LRG1 on HIF-1α expression and test the hypothesis
that HIF-1α is involved in LRG1-induced EMT and
angiogenesis in CRC.
Methods
Cell culture and LRG1 treatment
Human colorectal carcinoma cell lines, SW480 and
HCT116, were cultured in RPMI 1640 medium supple-
mented with 10 % fetal bovine serum (FBS) in humidi-
fied 5.0 % CO2 atmosphere at 37 °C. Human umbilical
vein endothelial cells (HUVEC) were maintained in
DMEM containing 10 % FBS. Recombinant LRG1 was
purchased from R&D Systems and added into the cul-
ture medium at concentration of 50–1000 ng/ml for in-
dicated time before harvesting.
Small interfering RNA silencing
Transfection of siRNA was performed using Lipofecta-
mine 2000 (Invitrogen, USA) according to the manufac-
turer’s protocol. The transfection reagent was replaced by
complete medium after incubation for 6 h, and cells were
harvested 24 h or 48 h later. The siRNA oligos for LRG1
(#1: sense, 5′-CCUCUAAGCUCCAAGAAUUTT-3′ and
antisense, 5′-AAUUCUUGGAGCUUAGAGGTT-3′; #2:
sense, 5′-GCAAUUAGAACGGCUACAUT T-3′ and anti-
sense, 5′-AUGUAGCCGUUCUAAUUGCTT-3′), HIF-1ɑ
(#1: sense, 5′-GGAA AGAGACUCAUAGAAA-3′ and anti-
sense, 5′-UUUCUAUGACUCUCUUUCC-3′; #2: sense,
5′-GCACAGGCCACATTCACGTATAT-3′ and antisense,
5′- GGTTCACAAATCAGC ACCAAGC-3′), and a non-
targeting control siRNA were purchased from GenePharma
(China).
RNA extraction and quantitative real-time PCR
Total RNA was extracted by Trizol (Invitrogen, USA),
and cDNA was synthesized using the PrimeScript TM
RT Reagent Kit (Perfect Real Time, TaKaRa, Japan).
Quantitative real-time PCR was performed in a 10ul
total volume containing SYBR Green (SYBR® Premix Ex
Taq TM II, TaKaRa, Japan) on an Applied Biosystems
7900 quantitative PCR system. The primers used were as
follows: LRG1, 5′-GTTGGAGACCTTGCCACCT-3′ and
5′-GCTTGTTGCCGTTCAGGA-3′; HIF-1α, 5′-TGCTA
ATGCCACCACTACC-3′ and 5′-TG ACTCCTTTTCCT
GCTCTG-3′; VEGF-A, 5′-CTTTCTGCTGTCTTGGGT
G-3′ and 5′-ACT TCGTGATGATTCTGCC-3′; Twist1,
5′-AGTCCGCAGTCTTACGAGGA-3′ and 5′-GCCAG
CTTGAGGGTCTGAAT-3′; E-cadherin, 5′-TACACTGC
CCAGGAGCCAGA-3′ and 5′-TGG CACCAGTGTCCG
GATTA-3′; N-cadherin, 5′-TTTGATGGAGGTCTCCTA
ACACC-3′ and 5′-ACGTTTAACACGTTGGAAATGT
G-3′; VDR, 5′-GATGCCCACCACAAGACCTA-3′ and
5′-CGGTTCCATCATGTCCAGTG-3′; Vimentin, 5′-TG
AGTACCGGAGACAGGTGCA G-3′ and 5′-TAGCAGC
TTCAACGGCAAAGTTC-3′; α-SMA, 5′-CGTGGCTAC
TCCTTCGT G-3′ and 5′-TGATGACCTGCCCGTCT-3′;
β-actin, 5′-TGGCACCCAGCACAATGAA-3′ and 5′-CT
AAGTCATAGTCCGCCTAGAAGCA-3′. Relative expres-
sion of each specific gene was determined in accordance
with the 2−ΔΔCt method, using β-actin as the internal stand-
ard. Each experiment was performed as triplicate, and data
was presented as mean ± SEM.
Clinical specimens and immunohistochemistry
Human CRC tissues and adjacent non-cancerous tis-
sues were obtained from patients who underwent surgi-
cal resection at Renji Hospital. Histological diagnoses
were performed by expert pathologists. The study was
approved by the Ethics Committee of Renji hospital,
and written informed consent was obtained from all pa-
tients included in this study.
Paraffin-embedded specimens of 68 colorectal cancers
and 32 normal colorectal tissues were selected for
immunohistochemistry. Briefly, antigen retrieval was
performed with 10 mM citrate buffer (Ph 6.0) using
microwave. Sections were incubated with anti-LRG1
antibody (1:100, Abcam, USA) overnight at 4 °C, followed
by HRP-conjugated secondary antibody. LRG1 expression
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was quantified based on the intensity of staining (scored
as: 0, no staining; 1, weak staining; 2, moderate staining; 3,
strong staining) and the percentage of positive tumor cells
(scored as: 0, less than 5 %; 1, 5–25 %; 2, 26–50 %; 3, >
51 %). The final score was calculated as the product of
two parameters, and at least 3 points was considered as
positive.
Invasion and migration assay in vitro
The cell invasion assay was carried out using chambers
with filters (pore size of 8-um), coated with Matrigel.
The cells (2*105 cells per well) were seeded into the
upper chamber in serum-free medium, while medium
with 20 % FBS was applied to the lower chamber. For
endothelial cells, conditioned medium was added to the
lower chamber. After incubation for 48 h, invasive cells
on the bottom surface of the membrane were fixed with
4 % formaldehyde, stained with crystal violet, and counted
in five random microscopic fields for each replicate
(original magnification, 200×).
The migration ability of cells was measured through
wound healing assay. Cells were cultured in 6-well plates
to reach 90 % confluence. The cell monolayers were
scraped with a 100-ul pipette tip, washed twice with
PBS, and cultured in serum-free medium. After 24 h and
48 h, the scratch area was photographed (original mag-
nification, 200×).
Conditioned medium and enzyme-linked immunosorbent
assay
CRC cells cultured in 6-well plates were treated with LRG1
for 24 h. Thereafter, cells were washed three times and
changed to fresh serum-free medium for additional 24 h.
The supernatants were harvested, centrifuged at 3500 rpm
for 5 min, and stored at−80 °C until used as conditioned
medium (CM). Tumor-derived VEGF-A in the medium
was quantified by enzyme-linked immunosorbent assay
(ELISA). VEGF-A concentration was determined using
ELISA Kit (R&D Systerms Europe, UK) according to the
manufacturer’s instructions.
Endothelial cell tube formation assay
Matrigel (BD Biosciences, CA) was laid into a 48-well plate
and polymerized at 37 °C for 30 min. Then, 3 × 104
HUVECs were seeded into each well of pre-coated 48-well
plate and incubated with conditioned medium. After 8 h,
capillary-like tubes were photographed (original magnifica-
tion, 100×) from four randomly chosen fields, and the total
number of complete tubular structures was quantified.
Aortic ring sprouting assay
Aortas were excised from 8-week-old Sprague–Dawley
rats and dissected into rings of 1 mm. Aortic rings were
embedded in Matrigel (BD Biosciences, California, USA)
in a 48-well culture plate. CM was added to the wells in
a final volume of 200ul culture medium. The aortic rings
were incubated at 37 °C for 6 days with medium re-
placed every other day. On day 6, the microvessel
sprouting was photographed and scored from 0 (least
positive) to 5 (most positive) in a double-blinded man-
ner as previously described [20]. Three independent
experiments were carried out with five rings per group
in each assay. Representative micrographs were shown.
Western blot
Whole-cell protein extracts were prepared with RIPA
buffer containing a protease inhibitor mixture. Protein
concentrations were determined using BCA Protein Assay.
Equal amounts of total protein were separated by SDS–
polyacrylamide gel electrophoresis, transferred onto the
polyvinylidene difluoride membrane, and blocked with 5 %
fat-free milk. The membranes were incubated with primary
antibodies overnight at 4 °C, followed by HRP-conjugated
secondary antibodies for 1 h at room temperature. The im-
mune complexs were detected using a chemiluminescence
kit (SuperSignal ECL Kit, Thermo Fisher, USA). Antibody
for LRG1 was purchased from Abcam (USA), and other
antibodies were all purchased from Cell Signaling Technol-
ogy Inc (USA). Intensity of the protein bands was quanti-
fied by Image J software and normalized to that of β-actin.
Statistical analysis
Statistical analysis was carried out using SPSS 20.0 soft-
ware (SPSS, Chicago, IL, USA). Quantitative data were
expressed as the means ± SEM, and comparisons between
every two groups were performed with Student t test or
paired t test. The association between LRG1 staining and
the clinicopathologic features of CRC patients were exam-
ined by Chi-square tests. P-value <0.05 was considered
statistically significant.
Results
LRG1 expression was increased in human CRCs and
correlated with tumor progression
To investigate the mRNA expression level of LRG1 in
CRC, we analysed the microarray data from two Oncomine
Cancer Microarray databases (GSE20916 and GSE20842)
and revealed remarkable overexpression of LRG1 in CRC
tissues than normal tissues (Fig. 1a). Next, we performed
real-time RT-PCR to assess LRG1 expression in 30 cases of
CRC tissues and matched normal tissues. Similar result
was observed that LRG1 was significantly overexpressed in
CRC tissues, compared with corresponding normal tis-
sues (P < 0.0001, Fig. 1b). Immunohistochemistry was
performed to examine LRG1 protein in 68 CRC and 32
normal paraffin-embedded tissues. Positive staining of
LRG1 was mainly distributed in the cytoplasm and cy-
tomembrane of CRC cells (Fig. 1c). Positive expression
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rate of LRG1 was 66.18 % (45/68) in CRC tissues, signifi-
cantly higher than that of normal colorectal mucosa
(31.25 %, 12/32) (P = 0.007). The clinicopathologic features
of the 68 CRCs were summarized in Table 1. LRG1 expres-
sion was significantly correlated with deeper invasion
depth (P = 0.032) and lymph node metastasis (P = 0.013).
Fig. 1 LRG1 was overexpressed in CRC tissues. a Overexpression of LRG1 mRNA in CRC tissues than normal tissues based on the microarray data
from GSE20916 and GSE20842. b RT-PCR analysis of LRG1 mRNA expression in 30 pairs of CRC and adjacent non-tumor tissues. The expression
levels of LRG1 were normalized to those of β-actin (P < 0.0001, paired t test). c Representative immunohistochemical staining of LRG1 in human
samples of normal tissue, early CRC tissue, and advanced CRC tissue (Original magnification: ×200 and 400×). Scale bar represents 50 μm
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There was no significant correlation between LRG1 ex-
pression and other clinicopathological characteristics,
including age, gender, location, tumor size and distal
metastasis.
LRG1 influenced CRC cell migration, invasion and EMT
The overexpression of LRG1 in CRCs suggested that
LRG1 might play a role in its migration and invasion
capability. To investigate the function of LRG1 in CRC
cells, we knocked down LRG1 by transfection of specific
siRNA. Both mRNA and protein levels of LRG1 were ef-
ficiently depleted in HCT116 and SW480 cells (Fig. 2a).
Transwell and wound healing assay were used to exam-
ine invasion and migration of CRC cells. In transwell as-
says, knockdown of LRG1 significantly reduced the
number of cells invaded through the membrane com-
pared with the control (Fig. 2b). Likewise, wound closure
ratio was markedly reduced to 48 and 61 % respectively
(P both <0.05) in LRG1-siRNA transfected HCT116
and SW480 cells (Fig. 2c). Next, we examined the
expression of EMT markers following knockdown of
LRG1. Real-time RT-PCR and western blot analysis
showed that epithelial biomarkers of E-cadherin and
VDR were increased in LRG1-depleted CRC cells, whereas
mesenchymal biomarkers of N-cadherin, α-SMA and
Vimentin were decreased. Furthermore, we investigated
whether the EMT-related transcription factors were in-
volved in LRG1-promoted EMT. Results showed that
Twist1 expression was significantly decreased by LRG1
knockdown in both cell lines (Fig. 3a and b). These results
suggested that LRG1 can enhance CRC cell invasion and
induce EMT.
LRG1 supplementation enhanced expression and
secretion of VEGF-A and promotes endothelial cells
migration and tube formation
Angiogenesis is an essential step in tumor metastasis.
Given that LRG1 was reported to be a new regulator of
angiogenesis, we determined whether LRG1 was involved
in CRC angiogenesis. Our data implied that treatment
with human rLRG1 for 24 h concentration- dependently
increased VEGF-A mRNA expression and protein secre-
tion level in both SW480 and HCT116 cells (Fig. 4a).
Similarly, VEGF-A expression was elevated by stimulation
with rLRG1 in a time-dependent manner (Fig. 4b). To fur-
ther investigate the role of LRG1 in angiogenesis, we col-
lected the CM derived from HCT116 cells incubated in
the presence or absence of rLRG1 (500 ng/ml). The CM
was then applied to HUVECs for transwell migration, tube
formation and aortic ring sprouting assays. As shown in
Fig. 4c, CM from CRC cells exposed to LRG1 promoted
endothelial cell migration. In tube formation assays, the
cumulative number of tubular structures formed by
HUVECs in CM from LRG1-treated CRC cells was signifi-
cantly increased (2.6 fold, Fig. 4d). Microvessel sprouting
from aortic rings was significantly stimulated in the pres-
ence of CM from LRG1-treated CRC cells (Fig. 4e). In
these assays, the promotion effect of LRG1 on endothelial
cell behaviors was blocked by LRG1 mAb. These results
provided evidence for the role of LRG1 in promotion of
angiogenic capability in colorectal carcinomas.
HIF-1α was essential for LRG1-mediated EMT and
angiogenesis
HIF-1α was a critical regulator in both tumor angiogen-
esis and hypoxia-induced EMT. To examine whether
LRG1 would enhance HIF-1α expression, CRC cells
were treated with rLRG1 for 24 h. HIF-1α mRNA ex-
pression was induced at 100 ng/ml and reached the
maximum level at 1000 ng/ml (Fig. 5a). Protein expres-
sion of HIF-1α was also increased following stimulation
with rLRG1 in a concentration-dependent manner in
SW480 cells. LRG1 stimulation also resulted in in-
creased expression of VEGF-A, Twist1 and N-cadherin,
while decreased E-cadherin expression (Fig. 5b). Further
we determined the role of HIF-1α in LRG1-induced
VEGF-A overexpression and EMT. Transfection with
Table 1 Correlation between LRG1 expression and
clinicopathological parameters of CRCs
n LRG1 expression P values
Negative Positive
Age
< 60 37 12 25 0.791
≥ 60 31 11 20
Gender
Male 41 13 28 0.649
Female 27 10 17
Location
Right colon 21 9 12 0.396
Left colon 18 4 14
Rectum 29 10 19
Tumor diameter
< 5 cm 35 11 24 0.667
≥ 5 cm 33 12 21
T stage
T1 + T2 32 15 17 0.032
T3 + T4 36 8 28
Lymph nodes metastasis
Negative 39 18 21 0.013
Positive 29 5 24
Distant metastasis
Negative 63 23 40 0.242
Positive 5 0 5
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siRNA successfully silenced the mRNA and protein
levels of HIF-1α expression in SW480 cells (Fig. 5c).
Secretion of VEGF-A by SW480 cells was elevated in the
presence of LRG1, and the effect was abolished by
knockdown of HIF-1α (Fig. 5d). Knockdown of HIF-1α
also reversed LRG1-induced EMT phenotype, increas-
ing E-cadherin expression, and decreasing Twist1 and
N-cadherin expression (Fig. 5e). As shown in Fig. 5f, si-
lencing HIF-1α inhibited the enhanced invasion ability
of CRC cells induced by LRG1. These results strongly
implied that HIF-1α is implicated in LRG1-induced
CRC cells invasiveness, EMT and angiogenesis.
Discussion
It was reported that plasma levels of LRG1 in patients
with CRC were higher than those with adenomatous
polyps, which might be a novel biomarker for the pro-
gression from colorectal adenoma to carcinoma [21]. In
Fig. 2 Knockdown of LRG1 repressed the invasion capacity of CRC cells. a RT-PCR and Western blot analyses showed effective downregulation of
LRG1 following siRNA transfection. b HCT116 and SW480 cells transfected with LRG1 siRNA or control siRNA were seeded in the upper chamber.
After 48 h, the cells invaded through the membrane were stained and counted in five random microscopic fields (200×). c LRG1- and control-siRNA
transfected HCT116 and SW480 cells were wounded with pipette and wound closure percentage was quantified 48 h after scratch relative to
that at 0 h. *P < 0.05 compared to the control cells. Scale bar represents 100 μm
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our study, we demonstrated that LRG1 expression was
significantly increased in CRC tissues compared with
normal tissues. In addition, expression level of LRG1
was positively associated with deeper invasion depth and
lymphatic metastasis. These results imply that LRG1
may be involved in colorectal cancer initiation and pro-
gression, which is in agreement with published studies
of ovarian cancer and biliary tract cancer [10, 11]. How-
ever, LRG1 has been reported to act as a tumor suppres-
sor in hepatocellular carcinoma and endometrial
carcinoma [22, 23]. The discrepancy of LRG1 function
in certain kinds of cancers may be due to its tissue
specificity.
Although LRG1 is found to be implicated in various
kinds of malignant carcinomas and benign diseases, the
biological functions of LRG1 have not been fully eluci-
dated. LRG1 has been predicted to play a role in cell ad-
hesion and cell migration due to its leucine-rich repeats
and tendency to bind extracellular matrix proteins [24].
A recent study showed that LRG1 promoted prolifera-
tion, migration and invasion of glioma cells, as well as
downregulated the expression of E-cadherin [25]. Our
experiments demonstrated that knockdown of LRG1 by
siRNA significantly attenuated the migratory and inva-
sive potency of CRC cells. Moreover, depletion of LRG1
caused a shift from mesenchymal markers to epithelial
markers, which was upregulation of E-cadherin and
VDR, and downregulation of N-cadherin, α-SMA and
Vimentin. Meanwhile, stimulation with recombinant
LRG1 induced EMT and enhanced cell invasion. The
expression of Twist1, a well known EMT-promoting
transcriptional factor, was also found to be positively
regulated by LRG1. Our findings identified LRG1 as a
novel inducer of EMT and a potential enhancer of the
metastatic potential in colorectal cancer.
Sustained angiogenesis is known as an essential part in
the unrestrained growth of tumors and metastasis of
cancer cells to distant organs. It has been reported that
LRG1 influences endothelial cells proliferation, migra-
tion, tube formation, and promotes blood vessel growth
in ex vivo models of angiogenesis [7]. Whether LRG1
could regulate angiogenesis and be a promising anti-
angiogenic therapy target in colorectal cancer were un-
known. Our study revealed that treatment of CRC cells
with rLRG1 induced the expression of critical pro-
angiogenic molecules including HIF-1α and VEGF-A.
Fig. 3 Knockdown of LRG1 prevents the mesenchymal transition. a and b Expression of EMT-associated markers in CRC cells with LRG1 siRNA or
control siRNA were measured by RT-PCR and western blot assays. *P < 0.05 compared to the control cells
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Fig. 4 LRG1 promoted VEGF-A expression and angiogenesis. a HCT116 and SW480 cells were stimulated with rLRG1 (0–1000 ng/ml) for 24 h, and
VEGF-A expression was quantified by RT-PCR and ELISA. b CRC cells were stimulated with rLRG1 (500 ng/ml) for indicated hours, and VEGF-A
expression was quantified by RT-PCR and ELISA. c and d The medium of HCT116 cells incubated in the presence or absence of LRG1 (500 ng/ml)
and LRG1 antibody (10 μg/ml) was collected and then applied to HUVECs for transwell migration assay and tube formation assay. e Effect of CM from
LRG1-induced HCT116 cells on the aortic ring sprouting assay. Representative photos were shown and data were summarized from 3 independent
experiments. *Compared to the control group, P < 0.05. Scale bar represents 100 μm
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Cytokines derived from the tumor microenvironment
could facilitate the activities of endothelial cells and pro-
mote angiogenesis [26, 27]. Therefore, we used the con-
ditional medium from CRC cells to determine whether
LRG1 expression modulated endothelial cell migration
and tube formation, both of which are critical indicators
of angiogenic ability. We found that endothelial cell cul-
tured with CM from rLRG1-stimulated CRC cells exhib-
ited an increased migration and tube formation capacity.
Taken together, our results indicated that overexpression
of LRG1 in CRC cells might promote the secretion of
pro-angiogenic factors like VEGF-A, thus contributing
Fig. 5 The role of HIF-1α in LRG1-induced EMT and VEGF-A expression. a HIF-1α mRNA expression in HCT116 and SW480 cells stimulated with
indicated concentrations of LRG1 for 24 h was measured by RT-PCR. β-actin was used as the internal control. b The protein levels of HIF-1α,
Twist1, E-cadherin, and N-cadherin in response to LRG1 in SW480 cells were measured by western blot. c HIF-1α expression was knocked down in siRNA-
transfected SW480 cells at both mRNA and protein levels. d SW480 cells were transfected with HIF-1α or control siRNA for 24 h, and treated
with or without rLRG1 (500 ng/ml) for additional 24 h. Secretion of VEGF-A from SW480 cells was quantified by ELISA. e HIF-1α, VEGF-A, E-cadherin,
N-cadherin and Twist1 expressions were detected by western blot. f SW480 cells were harvested and applied for transwell invasion assays. The numbers
of invasive cells (five random fields) were expressed as means ± SEM of three independent experiments. *Compared to the control group, P < 0.05. Scale
bar represents 100 μm
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to CRC angiogenesis. Further studies with in vivo experi-
ments are needed to demonstrate the biological role of
LRG1 in CRC angiogenesis and metastasis.
In this study, we found that treatment of CRC cells
with LRG1 promoted the mRNA and protein expression
of HIF-1α. Hypoxia or overexpression of HIF-1α is asso-
ciated with resistance to cancer chemotherapy and in-
creased patient mortality [28]. HIF-1α was reported to
be overexpressed in CRC and correlated with poor prog-
nosis [29, 30]. Since the critical role of HIF-1α in tumor
progression and metastasis, inhibition of HIF-1α was
considered as a promising therapeutic strategy. HIF-1α,
the regulatory subunit of HIF-1, is mainly regulated in
an oxygen-dependent manner. HIF-1α is rapidly de-
graded under normoxic conditions through various
post-translational modifications of hydroxylation, ubi-
quitination and ultimate proteasomal degradation [31].
However, several stimuli such as EGF, TGF-β, and IGF-
1 can induce HIF-1α accumulation under normoxia, at
various levels of transcription, translation, and protein
stability in a cell-type-specific manner [32–34]. Consist-
ent with the role of HIF-1α in inducing EMT and meta-
static phenotypes, our results indicated HIF-1α to be
involved in LRG1-induced EMT, since knockdown of
HIF-1α blocked the mesenchymal phenotype and invasive
capacity induced by LRG1. Moreover, HIF-1α knockdown
abrogated the LRG1-induced VEGF-A expression, which
acts as a key downstream target of HIF-1α. These data
suggested that LRG1 may target the HIF-1α pathway to
induce CRC cell invasion and angiogenesis. A recent study
showed that LRG1 overexpression activated the canonical
TGF-β signaling pathway and enhanced the invasiveness
of glioma cells, which could be reversed by TGF-β signal-
ing pathway inhibitor [24]. It has been shown that TGF-β
stimulates HIF-1α accumulation and that HIF-1α medi-
ates TGF-β-induced EMT [35]. It is not clear whether
LRG1 activates the transcription of HIF-1α directly or via
TGF-β pathway.
Conclusion
In summary, this is a preliminary study to investigate the
role of LRG1 in colorectal cancer. Our results provided
evidence for LRG1 function as a novel inducer of EMT
and angiogenesis in colorectal cancer, which was at least
partially through promotion of HIF-1α expression. Thus,
LRG1 may be a potential biomarker and therapeutic target
for colorectal cancer. Further researches are still needed
to clarify the molecular mechanisms and therapeutic ben-
efits of LRG1 on CRC and other malignancies.
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